Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAREGIVER: Palbociclib in TNBC
NCT05067530Phase 2Not yet recruiting
- Sponsor
- Medical University of Gdańsk
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in triple-negative breast cancer (TNBC), sponsored by Medical University of Gdańsk. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
palbociclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05067530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067530.